Equity Profile

REGN

Regeneron Pharmaceuticals, Inc.

Health CareBiotechnology$69.5B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for its long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

REGN Q2-2026 Earnings Preview

Context

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative medicines for serious diseases. Operating in the health care sector, Regeneron is known for its strong pipeline of therapies and its commitment to research and development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+42.98%

Avg Stock Reaction

-0.40%

Last Quarter Recap

In Q1 2026, Regeneron reported an impressive EPS of $9.47, significantly beating estimates by 50.7%. However, the stock dropped 6.21% the following day, indicating market caution despite strong earnings.

Management Promises & Guidance

Continued focus on expanding its drug pipeline.
Commitment to maintaining high levels of research and development investment.
Plans to enhance market access for its existing products.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Regeneron's upcoming earnings, given its history of beating EPS estimates. However, concerns about revenue growth and market reactions to past earnings surprises may temper enthusiasm.

Bull Case

If Regeneron continues its trend of beating EPS estimates and provides positive updates on its drug pipeline, it could see significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it may face a sharp decline in stock price, especially given past market reactions.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

Given Regeneron's history of beating EPS estimates, this number will be crucial for market sentiment and stock performance.

What updates will management provide on the drug pipeline?

Insights into the pipeline can greatly influence future revenue expectations and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Regeneron's potential for revenue growth based on its robust pipeline and recent successful drug launches.

Supporting Evidence

Regeneron has consistently beaten EPS estimates, suggesting strong operational execution.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Recent insider buying could signal confidence in the company's future performance.

Key Risk

If the drug pipeline shows unexpected advancements, it could significantly alter revenue projections.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Regeneron can maintain its strong earnings performance while also addressing revenue growth concerns.

Bull Confirmed If

An EPS of $10.00 or higher would confirm the bull case and likely lead to a positive market reaction.

Bear Confirmed If

An EPS below $8.00 would confirm the bear case and could lead to a significant stock decline.

Pre-Earnings Positioning

Options Market

Implied Move

±13.2%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±13.2% while REGN has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

41.1%

Calls (71K)P/C Ratio: 0.36Puts (80K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regeneron beats expectations, history suggests the stock could rise by around 5.4% on the day, confirming a strong growth outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction, reflecting investor uncertainty.

Miss

If the company misses EPS estimates, history suggests a potential decline of around 6.9%, which could trigger further selling pressure.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-LAJulia LetlowRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new drug approvals or clinical trial results.
2Any changes to revenue guidance for the upcoming quarters.
3Insights into market competition and how Regeneron plans to respond.
4Updates on partnerships or collaborations that could enhance growth.
5Management's outlook on the overall biotechnology market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for its long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

REGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+42.98%

Avg Stock Reaction

-0.40%

Last Quarter Recap

Management Promises & Guidance

Continued focus on expanding its drug pipeline.
Commitment to maintaining high levels of research and development investment.
Plans to enhance market access for its existing products.

Expectations

Wall Street Expectations

Bull Case

If Regeneron continues its trend of beating EPS estimates and provides positive updates on its drug pipeline, it could see significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it may face a sharp decline in stock price, especially given past market reactions.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

Given Regeneron's history of beating EPS estimates, this number will be crucial for market sentiment and stock performance.

What updates will management provide on the drug pipeline?

Insights into the pipeline can greatly influence future revenue expectations and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Regeneron's potential for revenue growth based on its robust pipeline and recent successful drug launches.

Supporting Evidence

Regeneron has consistently beaten EPS estimates, suggesting strong operational execution.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Recent insider buying could signal confidence in the company's future performance.

Key Risk

If the drug pipeline shows unexpected advancements, it could significantly alter revenue projections.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Regeneron can maintain its strong earnings performance while also addressing revenue growth concerns.

Bull Confirmed If

An EPS of $10.00 or higher would confirm the bull case and likely lead to a positive market reaction.

Bear Confirmed If

An EPS below $8.00 would confirm the bear case and could lead to a significant stock decline.

Pre-Earnings Positioning

Options Market

Implied Move

±13.2%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±13.2% while REGN has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

41.1%

Calls (71K)P/C Ratio: 0.36Puts (80K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regeneron beats expectations, history suggests the stock could rise by around 5.4% on the day, confirming a strong growth outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction, reflecting investor uncertainty.

Miss

If the company misses EPS estimates, history suggests a potential decline of around 6.9%, which could trigger further selling pressure.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-LAJulia LetlowRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new drug approvals or clinical trial results.
2Any changes to revenue guidance for the upcoming quarters.
3Insights into market competition and how Regeneron plans to respond.
4Updates on partnerships or collaborations that could enhance growth.
5Management's outlook on the overall biotechnology market.